PEN (Penumbra, Inc.) Stock Financials & Earnings | Market Cap Arena

PEN (Penumbra, Inc.) Stock Financials & Earnings | Market Cap Arena

PENPenumbra, Inc.

Mkt Cap$13B

Healthcare·Medical - Devices·🇺🇸 United States·NYSE

Revenue (TTM)$1.4B

Net Income (TTM)$178M

EPS (TTM)$4.52

Free Cash Flow (TTM)$175M

Gross Margin67.1%

Op. Margin13.5%

Net Margin12.7%

FCF Margin12.5%

P/S Ratio (TTM)9.5x

P/E Ratio (TTM)74.7x

YoY Rev Growth+17.5%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$241M	$151M	$8M
Q2 23	$261M	$167M	$18M
Q3 23	$271M	$178M	$13M
Q4 23	$285M	$187M	$35M
Q1 24	$279M	$181M	$12M
Q2 24	$299M	$163M	-$81M
Q3 24	$301M	$200M	$35M
Q4 24	$316M	$211M	$43M
Q1 25	$324M	$216M	$40M
Q2 25	$339M	$224M	$41M
Q3 25	$355M	$240M	$49M
Q4 25	$385M	$262M	$59M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	15.0x	2047.3x
Q2 23	14.1x	455.5x
Q3 23	13.3x	326.7x
Q4 23	12.5x	145.9x
Q1 24	12.1x	142.1x
Q2 24	11.7x	932.2x
Q3 24	11.4x	384.1x
Q4 24	11.1x	947.0x
Q1 25	10.7x	314.2x
Q2 25	10.4x	89.8x
Q3 25	9.9x	80.9x
Q4 25	9.5x	74.7x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	$13M	$9M
Q2 23	$17M	$13M
Q3 23	$31M	$28M
Q4 23	$36M	$33M
Q1 24	$38M	$32M
Q2 24	$23M	$18M
Q3 24	$56M	$51M
Q4 24	$51M	$46M
Q1 25	$49M	$36M
Q2 25	$45M	$29M
Q3 25	$58M	$42M
Q4 25	$86M	$68M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$4M
Q2 23	$4M
Q3 23	$3M
Q4 23	$4M
Q1 24	$6M
Q2 24	$5M
Q3 24	$5M
Q4 24	$5M
Q1 25	$13M
Q2 25	$16M
Q3 25	$16M
Q4 25	$18M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+18.4%	+12.2%
Q2 23	+25.5%	+16.8%
Q3 23	+26.8%	+24.0%
Q4 23	+28.7%	+15.4%
Q1 24	+15.4%	+14.2%
Q2 24	+14.5%	+56.1%
Q3 24	+11.1%	+2.8%
Q4 24	+10.8%	+9.3%
Q1 25	+16.3%	+6.5%
Q2 25	+13.4%	-21.5%
Q3 25	+17.8%	+15.1%
Q4 25	+22.1%	+19.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$13M	5.3%
Q2 23	$13M	4.9%
Q3 23	$14M	5.2%
Q4 23	$0	0.0%
Q1 24	$14M	4.9%
Q2 24	$10M	3.2%
Q3 24	$11M	3.6%
Q4 24	$12M	3.8%
Q1 25	$14M	4.3%
Q2 25	$14M	4.2%
Q3 25	$16M	4.5%
Q4 25	$15M	4.0%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$20M	$123M
Q2 23	$22M	$127M
Q3 23	$21M	$126M
Q4 23	$22M	$130M
Q1 24	$25M	$144M
Q2 24	$25M	$142M
Q3 24	$25M	$140M
Q4 24	$20M	$148M
Q1 25	$22M	$153M
Q2 25	$23M	$160M
Q3 25	$23M	$169M
Q4 25	$22M	$181M

Revenue Segments

Quarter	Neuro	Peripheral Vascular
Q1 23	$99M	$143M
Q2 23	$109M	$153M
Q3 23	$171M	$100M

Revenue by Geography

Quarter	Other Non-US	United States
Q1 23	$70M	$172M
Q2 23	$75M	$187M
Q3 23	$76M	$195M
Q4 23	$81M	$204M
Q1 24	$69M	$210M
Q2 24	$81M	$218M
Q3 24	$75M	$226M
Q4 24	$68M	$248M
Q1 25	$67M	$257M
Q2 25	$79M	$261M
Q3 25	$80M	$275M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$95M	$104M	$199M
Q2 23	$114M	$107M	$221M
Q3 23	$101M	$148M	$249M
Q4 23	$167M	$122M	$289M
Q1 24	$223M	$90M	$313M
Q2 24	$288M	$51M	$340M
Q3 24	$280M	$11M	$291M
Q4 24	$324M	$16M	$340M
Q1 25	$376M	$3M	$379M
Q2 25	$422M	$3M	$425M
Q3 25	$321M	$149M	$470M
Q4 25	$187M	$0	$187M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	39M	+0.5%
Q2 23	39M	+0.3%
Q3 23	39M	+0.0%
Q4 23	39M	+0.2%
Q1 24	39M	+0.2%
Q2 24	39M	-1.5%
Q3 24	39M	+1.0%
Q4 24	39M	+0.2%
Q1 25	39M	-0.3%
Q2 25	39M	+0.2%
Q3 25	39M	+0.1%
Q4 25	39M	+0.2%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	$169K	1K
FY 16	$176K	2K
FY 17	$196K	2K
FY 18	$202K	2K
FY 19	$203K	3K
FY 20	$170K	3K
FY 21	$197K	4K
FY 22	$217K	4K
FY 23	$252K	4K
FY 24	$265K	5K
FY 25	$299K	5K